Receptos, Inc.

10835 Road to the Cure
Suite #205

San Diego, CA  92121

Tel: 858.652.5700


Leadership:
Faheem Hasnain
President and CEO


Website:
www.receptos.com

Receptos, Inc.

Flagship Partners:  Doug Cole
Initial Investment: 
2009
Status: 
Public

Receptos (NASDAQ: RCPT) is a publicly traded biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases. The company's lead program, RPC1063, is a sphingosine 1-phosphate 1 receptor (S1P1R) small molecule modulator candidate for immune indications, including relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The company is also developing RPC4046, an anti-interleukin-13 (IL-13) antibody for an allergic/immune-mediated orphan disease, eosinophilic esophagitis (EoE). Receptos has established expertise in high resolution protein crystal structure determination, biology and drug discovery for G-protein-coupled receptors (GPCRs).

Doug Cole is on the Board of Directors.